Publications by authors named "De-Si Pan"
Histone deacetylase (HDAC) serves as a critical molecular regulator in the pathobiology of various malignancies and have garnered attention as a viable target for therapeutic intervention. A variety of HDAC inhibitors (HDACis) have been developed to target HDACs. Many preclinical studies have conclusively demonstrated the antitumor effects of HDACis, whether used as monotherapy or in combination treatments.
View Article and Find Full Text PDFType 2 diabetes mellitus is often treated with insulin-sensitizing drugs called thiazolidinediones (TZD), which improve insulin resistance and glycemic control. Despite their effectiveness in treating diabetes, these drugs provide little protection from eminent cardiovascular disease associated with diabetes. Here we demonstrate how chiglitazar, a configuration-restricted non-TZD peroxisome proliferator-activated receptor (PPAR) pan agonist with moderate transcription activity, preferentially regulates and , which are involved in glucose and lipid metabolism.
View Article and Find Full Text PDFArticle Synopsis
- Researchers developed a new multi-kinase inhibitor called CS2164, targeting key pathways involved in tumor growth and angiogenesis.
- CS2164 effectively inhibited several key kinases, resulting in reduced tumor blood vessel formation, cell proliferation, and differentiation of immune cells in tumors.
- In animal studies, CS2164 showed significant tumor growth inhibition and regression at manageable doses, suggesting potential as a promising cancer treatment.
Combination of low doses of histone deacetylases inhibitors and chemotherapy drugs is considered as one of the most promising strategies to increase the anticancer efficacy. Chidamide is a novel benzamide chemical class of HDAC inhibitor that selectively inhibited HDAC1, 2, 3 and 10. We sought to determine whether chidamide may enhance platinum-induced cytotoxicity in NSCLC cells.
View Article and Find Full Text PDFPurpose: Chidamide (CS055/HBI-8000) is a new histone deacetylase (HDAC) inhibitor of the benzamide class currently under clinical development in cancer indications. This study reports the in vitro and in vivo antitumor characteristics of the compound.
Methods: Selectivity and potency of chidamide in inhibition of HDAC isotypes were analyzed by using a panel of human recombinant HDAC proteins.